{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T08:10:08Z","timestamp":1744963808320,"version":"3.40.4"},"reference-count":29,"publisher":"Scientific Scholar","content-domain":{"domain":["surgicalneurologyint.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec id=\"st1\">\n<jats:title>Background<\/jats:title>\n<jats:p>The World Health Organization (WHO) classification of central nervous system (CNS) tumors is a major advance toward improving the diagnosis of adult brain tumors. Despite the promise of isocitrate dehydrogenase (IDH) mutations as an important biomarker for glioblastoma, not all institutions have ready access to mutation detection polymerase chain reaction (PCR) methods, and deoxyribonucleic acid (DNA) sequencing may be problematic in very small biopsies. However, a simultaneous evaluation of IDH1 status by DNA sequencing and immunohistochemistry (IHC) to determine the sensitivity and specificity of both methods, along with their predictive value, was unavailable.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st2\">\n<jats:title>Methods<\/jats:title>\n<jats:p>This retrospective study included 33 patients who underwent surgical resection or biopsy, January 2016\u2013December 2019. The diagnosis of glioblastoma was established. Surgically resected tumor tissues were fixated in 10%-formaldehyde preserved in paraffin-embedded blocks. Glioblastoma was classified according to the 2021 WHO classification of CNS tumors. The enrolled patients were followed up to obtain the overall survival rate (median follow-up time, 30 months).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st3\">\n<jats:title>Results<\/jats:title>\n<jats:p>Thirty-three patients (14 male; 19 female), mean age of 44.74 \u00b1 15.49 years. Eight had WHO Grade II, 2 with WHO Grade III, and 23 with WHO Grade IV. The sensitivity and specificity of IDH1 IHC were 81.82% (<jats:italic>P<\/jats:italic> = 0.0007), a positive predictive value of 90.00% (69.90-98.22%), and a negative predictive value of 69.23% (42.37-87.32%). The survival rate was significantly higher in IDH1 mutant than wild-type IDH1, whether based on IHC or PCR (<jats:italic>P<\/jats:italic> = 0.0014).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st4\">\n<jats:title>Conclusion<\/jats:title>\n<jats:p>IDH1 status evaluation is crucial to predicting the survival rate and important for guiding the treatment decision for patients with glioblastoma. Despite the lesser sensitivity and specificity of IHC in comparison to DNA sequencing in this study, larger prospective studies are needed to validate our preliminary finding.<\/jats:p>\n<\/jats:sec>","DOI":"10.25259\/sni_881_2024","type":"journal-article","created":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T07:40:06Z","timestamp":1744962006000},"page":"140","update-policy":"https:\/\/doi.org\/10.25259\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Poor diagnostic value of isocitrate dehydrogenase 1 R132H immunohistochemistry for determination of isocitrate dehydrogenase 1 status in patients with glioblastoma"],"prefix":"10.25259","volume":"16","author":[{"given":"Ahmad","family":"Faried","sequence":"first","affiliation":[{"name":"Department of Neurosurgery, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward Jaya","family":"Hadi","sequence":"additional","affiliation":[{"name":"Department of Anatomical Pathology, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasrayati","family":"Agustina","sequence":"additional","affiliation":[{"name":"Department of Anatomical Pathology, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10894","published-online":{"date-parts":[[2025,4,18]]},"reference":[{"key":"10.25259\/SNI_881_2024\/ref-1","doi-asserted-by":"crossref","first-page":"E13","DOI":"10.3171\/2014.9.FOCUS14505","article-title":"Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma","volume":"37","author":"Agnihotri","year":"2014","journal-title":"Neurosurg Focus"},{"key":"10.25259\/SNI_881_2024\/ref-2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3340\/jkns.2020.0071","article-title":"Analysis of mutant isocitrate dehydrogenase 1 immunoexpression, Ki-67 and programmed death ligand 1 in diffuse astrocytic tumours: Study of single center in Bandung, Indonesia","volume":"64","author":"Bolly","year":"2021","journal-title":"J Korean Neurosurg Soc"},{"key":"10.25259\/SNI_881_2024\/ref-3","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00401-009-0595-z","article-title":"Monoclonal antibody specific for IDH1 R132H mutation","volume":"118","author":"Capper","year":"2009","journal-title":"Acta Neuropathol"},{"key":"10.25259\/SNI_881_2024\/ref-4","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.pathol.2016.07.010","article-title":"IDH1\/2 gene hotspot mutations in central nervous system tumours: Analysis of 922 Chinese patients","volume":"48","author":"Chen","year":"2016","journal-title":"Pathology"},{"key":"10.25259\/SNI_881_2024\/ref-5","doi-asserted-by":"crossref","first-page":"116ra5","DOI":"10.1126\/scitranslmed.3002796","article-title":"Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas","volume":"4","author":"Elkhaled","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.25259\/SNI_881_2024\/ref-6","doi-asserted-by":"crossref","first-page":"100939","DOI":"10.1016\/j.inat.2020.100939","article-title":"Prognostic significance of L-type amino acid transported-1 (LAT-1) expression in human astrocytic gliomas","volume":"23","author":"Faried","year":"2021","journal-title":"Interdiscip Neurosurg"},{"key":"10.25259\/SNI_881_2024\/ref-7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s12253-014-9850-2","article-title":"Genetic analysis of a case of glioblastoma with oligodendroglial component arising during the progression of diffuse astrocytoma","volume":"21","author":"Hata","year":"2015","journal-title":"Pathol Oncol Res"},{"key":"10.25259\/SNI_881_2024\/ref-8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1101\/sqb.2016.81.031070","article-title":"Functional genomic characterization of cancer genomes","volume":"81","author":"Howard","year":"2016","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"10.25259\/SNI_881_2024\/ref-9","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/carcin\/bgz134","article-title":"Friend or foe-IDH1 mutations in glioma 10 years on","volume":"40","author":"Huang","year":"2019","journal-title":"Carcinogenesis"},{"key":"10.25259\/SNI_881_2024\/ref-10","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/B978-0-12-416618-9.00003-0","article-title":"Regulation of cancer metabolism by oncogenes and tumor suppressors","volume":"542","author":"Iurlaro","year":"2014","journal-title":"Methods Enzymol"},{"key":"10.25259\/SNI_881_2024\/ref-11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.gene.2014.10.027","article-title":"IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme","volume":"554","author":"Kalkan","year":"2015","journal-title":"Gene"},{"key":"10.25259\/SNI_881_2024\/ref-12","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/s41586-018-0389-3","article-title":"Human glioblastoma arises from subventricular zone cells with low-level driver mutations","volume":"560","author":"Lee","year":"2018","journal-title":"Nature"},{"key":"10.25259\/SNI_881_2024\/ref-13","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3390\/biomedicines8090294","article-title":"Isocitrate dehydrogenase mutations in glioma: Genetics, biochemistry, and clinical indications","volume":"8","author":"Liu","year":"2020","journal-title":"Biomedicines"},{"key":"10.25259\/SNI_881_2024\/ref-14","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO Classification of tumors of the central nervous system: A summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"10.25259\/SNI_881_2024\/ref-15","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/bpa.12832","article-title":"cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading","volume":"30","author":"Louis","year":"2020","journal-title":"Brain Pathol"},{"key":"10.25259\/SNI_881_2024\/ref-16","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1177\/107327481502200211","article-title":"Impending impact of molecular pathology on classifying adult diffuse gliomas","volume":"22","author":"Macaulay","year":"2015","journal-title":"Cancer Control"},{"key":"10.25259\/SNI_881_2024\/ref-17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s43042-024-00516-3","article-title":"Clinical impact of IDH1 mutations and MGMT methylation in adult glioblastoma","volume":"25","author":"Mahmoud","year":"2024","journal-title":"Egypt J Med Hum Genet"},{"key":"10.25259\/SNI_881_2024\/ref-18","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1053\/j.semdp.2024.05.001","article-title":"Review of immunohistochemistry techniques: Applications, current status, and future perspectives","volume":"41","author":"Mebratie","year":"2024","journal-title":"Semin Diagn Pathol"},{"key":"10.25259\/SNI_881_2024\/ref-19","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-12-3002","article-title":"The definition of primary and secondary glioblastoma","volume":"19","author":"Ohgaki","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.25259\/SNI_881_2024\/ref-20","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.molonc.2014.03.008","article-title":"Garbage in, garbage out: A critical evaluation of strategies used for validation of IHC biomarkers","volume":"8","author":"O\u2019Hurley","year":"2014","journal-title":"Mol Oncol"},{"key":"10.25259\/SNI_881_2024\/ref-21","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1080\/14737159.2018.1548935","article-title":"The clinical use of IDH1 and IDH2 mutations in gliomas","volume":"18","author":"Picca","year":"2018","journal-title":"Expert Rev Mol Diagn"},{"key":"10.25259\/SNI_881_2024\/ref-22","doi-asserted-by":"crossref","first-page":"16462","DOI":"10.18632\/oncotarget.24536","article-title":"IDH1 mutation is associated with lower expression of VEGF but not microvessel formation in glioblastoma multiforme","volume":"9","author":"Pol\u00edvka","year":"2018","journal-title":"Oncotarget"},{"key":"10.25259\/SNI_881_2024\/ref-23","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00401-014-1370-3","article-title":"ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an \u201cintegrated\u201d diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma","volume":"129","author":"Reuss","year":"2015","journal-title":"Acta Neuropathol"},{"key":"10.25259\/SNI_881_2024\/ref-24","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/PAI.0000000000000997","article-title":"IDH1\/2 mutations in patients with diffuse gliomas: A single center retrospective massively parallel sequencing analysis","volume":"30","author":"Sporikova","year":"2022","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.25259\/SNI_881_2024\/ref-25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/jjco\/hyaa162","article-title":"Survival in patients with glioblastoma at a first progression does not correlate with isocitrate dehydrogenase (IDH)1 gene mutation status","volume":"51","author":"Tabei","year":"2021","journal-title":"Jpn J Clin Oncol"},{"key":"10.25259\/SNI_881_2024\/ref-26","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/1477-7819-11-284","article-title":"Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients","volume":"11","author":"Takahashi","year":"2013","journal-title":"World J Surg Oncol"},{"key":"10.25259\/SNI_881_2024\/ref-27","first-page":"84543","article-title":"IDH-mutant gliomas","author":"Tateishi","year":"2019"},{"key":"10.25259\/SNI_881_2024\/ref-28","first-page":"1215","article-title":"The 2021 WHO Classification of tumors of the central nervous system: Clinical implications","volume":"23","author":"Wen","year":"2021","journal-title":"Neurooncology"},{"key":"10.25259\/SNI_881_2024\/ref-29","first-page":"477","article-title":"Comparison of immunohistochemistry and DNA sequencing for the detection of IDH1 mutations in gliomas","volume":"17","author":"Zou","year":"2015","journal-title":"Neuro Oncol"}],"container-title":["Surgical Neurology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/surgicalneurologyint.com\/poor-diagnostic-value-of-isocitrate-dehydrogenase-1-r132h-immunohistochemistry-for-determination-of-isocitrate-dehydrogenase-1-status-in-patients-with-glioblastoma\/","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/surgicalneurologyint.com\/surgicalint-articles\/poor-diagnostic-value-of-isocitrate-dehydrogenase-1-r132h-immunohistochemistry-for-determination-of-isocitrate-dehydrogenase-1-status-in-patients-with-glioblastoma\/","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,18]],"date-time":"2025-04-18T07:40:10Z","timestamp":1744962010000},"score":1,"resource":{"primary":{"URL":"http:\/\/surgicalneurologyint.com\/surgicalint-articles\/poor-diagnostic-value-of-isocitrate-dehydrogenase-1-r132h-immunohistochemistry-for-determination-of-isocitrate-dehydrogenase-1-status-in-patients-with-glioblastoma\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,18]]},"references-count":29,"alternative-id":["10.25259\/SNI_881_2024"],"URL":"https:\/\/doi.org\/10.25259\/sni_881_2024","relation":{},"ISSN":["2152-7806","2229-5097"],"issn-type":[{"value":"2152-7806","type":"electronic"},{"value":"2229-5097","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,18]]},"article-number":"140"}}